These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 7689290)

  • 1. Effect of resistance on combination chemotherapy for human immunodeficiency virus infection.
    Cox SW; Albert J; Ljungdahl-Ståhle E; Wahren B
    Adv Enzyme Regul; 1993; 33():27-36. PubMed ID: 7689290
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Loss of synergistic response to combinations containing AZT in AZT-resistant HIV-1.
    Cox SW; Albert J; Wahlberg J; Uhlén M; Wahren B
    AIDS Res Hum Retroviruses; 1992 Jul; 8(7):1229-34. PubMed ID: 1520536
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human immunodeficiency virus type 1 drug susceptibility during zidovudine (AZT) monotherapy compared with AZT plus 2',3'-dideoxyinosine or AZT plus 2',3'-dideoxycytidine combination therapy. The protocol 34,225-02 Collaborative Group.
    Larder BA; Kohli A; Bloor S; Kemp SD; Harrigan PR; Schooley RT; Lange JM; Pennington KN; St Clair MH
    J Virol; 1996 Sep; 70(9):5922-9. PubMed ID: 8709213
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Two-drug combinations of zidovudine, didanosine, and recombinant interferon-alpha A inhibit replication of zidovudine-resistant human immunodeficiency virus type 1 synergistically in vitro.
    Johnson VA; Merrill DP; Videler JA; Chou TC; Byington RE; Eron JJ; D'Aquila RT; Hirsch MS
    J Infect Dis; 1991 Oct; 164(4):646-55. PubMed ID: 1716649
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of evolutionary limitations of HIV-1 multidrug resistance to optimize therapy.
    Chow YK; Hirsch MS; Merrill DP; Bechtel LJ; Eron JJ; Kaplan JC; D'Aquila RT
    Nature; 1993 Feb; 361(6413):650-4. PubMed ID: 7679778
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multidrug-resistant human immunodeficiency virus type 1 strains resulting from combination antiretroviral therapy.
    Iversen AK; Shafer RW; Wehrly K; Winters MA; Mullins JI; Chesebro B; Merigan TC
    J Virol; 1996 Feb; 70(2):1086-90. PubMed ID: 8551567
    [TBL] [Abstract][Full Text] [Related]  

  • 7. pol mutations conferring zidovudine and didanosine resistance with different effects in vitro yield multiply resistant human immunodeficiency virus type 1 isolates in vivo.
    Eron JJ; Chow YK; Caliendo AM; Videler J; Devore KM; Cooley TP; Liebman HA; Kaplan JC; Hirsch MS; D'Aquila RT
    Antimicrob Agents Chemother; 1993 Jul; 37(7):1480-7. PubMed ID: 7689822
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Convergent combination therapy can select viable multidrug-resistant HIV-1 in vitro.
    Larder BA; Kellam P; Kemp SD
    Nature; 1993 Sep; 365(6445):451-3. PubMed ID: 7692302
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-HIV type 1 activity of 3'-fluoro-3'-deoxythymidine for several different multidrug-resistant mutants.
    Kim EY; Vrang L; Oberg B; Merigan TC
    AIDS Res Hum Retroviruses; 2001 Mar; 17(5):401-7. PubMed ID: 11282008
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase.
    St Clair MH; Martin JL; Tudor-Williams G; Bach MC; Vavro CL; King DM; Kellam P; Kemp SD; Larder BA
    Science; 1991 Sep; 253(5027):1557-9. PubMed ID: 1716788
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3'-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase.
    Tisdale M; Kemp SD; Parry NR; Larder BA
    Proc Natl Acad Sci U S A; 1993 Jun; 90(12):5653-6. PubMed ID: 7685907
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Response of Ethiopian human immunodeficiency virus type 1 isolates to antiviral compounds.
    Wondimu Z; Sönnerborg A; Ayehunie S; Britton S; Strannegård O
    Antiviral Res; 1992 Oct; 19(4):353-9. PubMed ID: 1281393
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy.
    Larder BA; Kemp SD; Harrigan PR
    Science; 1995 Aug; 269(5224):696-9. PubMed ID: 7542804
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synergistic inhibition of human immunodeficiency virus type 1 replication in vitro by two-drug and three-drug combinations of 3'-azido-3'-deoxythymidine, phosphonoformate, and 2',3'-dideoxythymidine.
    Kong XB; Zhu QY; Ruprecht RM; Watanabe KA; Zeidler JM; Gold JW; Polsky B; Armstrong D; Chou TC
    Antimicrob Agents Chemother; 1991 Oct; 35(10):2003-11. PubMed ID: 1722077
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synergistic combinations and peptides in the inhibition of human immunodeficiency virus.
    Cox S; Koshida R; Harmenberg J; Wahren B
    Adv Enzyme Regul; 1991; 31():85-97. PubMed ID: 1715118
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiretroviral combination treatment prolongs life in people with HIV/AIDS.
    Cooper EC
    AMFAR Rep; 1996 Jan; ():1-5. PubMed ID: 11363617
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 3TC/AZT: just another combination.
    GMHC Treat Issues; 1995 Dec; 9(12):2. PubMed ID: 11362997
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacodynamic studies (PD) of didanosine (ddI) alone and in combination with azidothymidine (AZT) in human T-cells; a stochastic biochemical approach to antiretroviral nucleoside drug combination in inhibiting HIV-reverse transcriptase (RT).
    Periclou AP; Nandy P; Avramis VI
    In Vivo; 2000; 14(3):377-88. PubMed ID: 10904870
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ganciclovir antagonizes the anti-human immunodeficiency virus type 1 activity of zidovudine and didanosine in vitro.
    Medina DJ; Hsiung GD; Mellors JW
    Antimicrob Agents Chemother; 1992 May; 36(5):1127-30. PubMed ID: 1510405
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro analysis of synergism and antagonism of different nucleoside/nucleotide analogue combinations on the inhibition of human immunodeficiency virus type 1 replication.
    Perez-Olmeda M; Garcia-Perez J; Mateos E; Spijkers S; Ayerbe MC; Carcas A; Alcami J
    J Med Virol; 2009 Feb; 81(2):211-6. PubMed ID: 19107982
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.